KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
A user experiencing hair loss since age 18 is considering switching from finasteride and minoxidil to dutasteride after poor results and lifestyle choices. They plan to improve their lifestyle and get blood work done to assess treatment effectiveness.
The user shared impressive hair regrowth results after 1.5 years using dutasteride (DUT) and oral minoxidil. They switched from finasteride and topical minoxidil due to lack of results and experienced no side effects.
The conversation is about a user ordering Dutas (dutasteride) from a website called emedicalwala, facing issues with the order and refund, and eventually receiving the product. The user advises against ordering from emedicalwala again despite finally receiving the softgels.
The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.
The conversation discusses the cost and insurance coverage of a comprehensive hormone and DHT blood panel for hair loss, with a focus on finasteride treatment. The user seeks a cheaper alternative to a $700 panel recommended in a video.
Switching from finasteride to dutasteride led to retrograde alopecia for some users, with mixed results on hair regrowth. Some experienced increased shedding, while others saw regrowth or no change.
The conversation discusses severe hair shedding and thinning, with the original poster using finasteride, oral minoxidil, and other supplements without improvement. The discussion highlights the possibility of telogen effluvium and the importance of addressing potential underlying health issues, such as stress and gut health, rather than assuming diffuse unpatterned alopecia (DUPA).
The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.
Dutasteride effectively reduces DHT levels and significantly increases testosterone levels. Users are cautious about adding oral minoxidil due to potential heart issues and are considering dosage adjustments with medical guidance.
The user is concerned about high estradiol and normal DHT levels after 6 months on finasteride and 4 months on weekly dutasteride, noticing hair thinning. They consider increasing dutasteride frequency and adding RU58841 to their regimen.
The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.
Dutasteride Mesotherapy shows promising hair growth results without affecting serum DHT levels, but the study's small sample size of six patients limits its reliability. The treatment is expensive and not widely available, with concerns about the lack of standardized procedures and long-term research.
The conversation discusses a user's positive experience with hair loss treatments, including Duoxidil, oral Dutasteride, oral Minoxidil, and biotin, noting no side effects and effective results. The user plans to start a new cycle of Dutasteride and PRP sessions.
DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
Dutasteride at 0.5mg blocks 50% of scalp DHT, while higher doses like 1mg and 2.5mg block more, with 2.5mg blocking up to 80%. Some users report better results with lower doses, and there's confusion about the effectiveness of different dosages on scalp versus serum DHT.
The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.
A dermatologist is developing a device to standardize hair progress photos for those using finasteride and minoxidil, aiming to provide consistent data on hair status. Users express skepticism about its practicality and cost, suggesting it might be more suitable for clinics than consumers.
The conversation is about experiences with Dutasteride Mesotherapy and its symptoms compared to oral dutasteride. Users discuss the effectiveness and side effects of this treatment for hair loss.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
Increasing dutasteride from 3x to 5x a week led to worse hair loss and higher DHT levels, prompting a return to the original dosing. The user also uses topical minoxidil and is addressing a folic acid deficiency.
The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.
A bodybuilder uses 1400mg testosterone weekly, 400mg equipoise, and GH, with 0.5mg dutasteride daily to stabilize hair loss and manage DHT levels. The user reports no side effects from dutasteride and finds it effective, while also discussing costs and effectiveness of other treatments like RU58841 and minoxidil.
The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.
The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.
The conversation is about hair loss treatment progress using dutasteride 0.5mg and oral minoxidil 3mg. Suggestions include adding topical minoxidil with tretinoin and considering micro needling or micro stamping for further improvement.